Merck & Co Inc
NYSE:MRK
Intrinsic Value
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. [ Read More ]
The intrinsic value of one MRK stock under the Base Case scenario is 135.96 USD. Compared to the current market price of 125.78 USD, Merck & Co Inc is Undervalued by 7%.
Valuation Backtest
Merck & Co Inc
Run backtest to discover the historical profit from buying and selling MRK stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Merck & Co Inc
Current Assets | 32.2B |
Cash & Short-Term Investments | 7.1B |
Receivables | 11.1B |
Other Current Assets | 14B |
Non-Current Assets | 74.5B |
Long-Term Investments | 1.5B |
PP&E | 23.1B |
Intangibles | 39.2B |
Other Non-Current Assets | 10.7B |
Current Liabilities | 25.7B |
Accounts Payable | 3.9B |
Accrued Liabilities | 15.2B |
Other Current Liabilities | 6.6B |
Non-Current Liabilities | 43.4B |
Long-Term Debt | 33.7B |
Other Non-Current Liabilities | 9.7B |
Earnings Waterfall
Merck & Co Inc
Revenue
|
60.1B
USD
|
Cost of Revenue
|
-15.9B
USD
|
Gross Profit
|
44.2B
USD
|
Operating Expenses
|
-40.1B
USD
|
Operating Income
|
4.1B
USD
|
Other Expenses
|
-3.7B
USD
|
Net Income
|
365m
USD
|
Free Cash Flow Analysis
Merck & Co Inc
What is Free Cash Flow?
MRK Profitability Score
Profitability Due Diligence
Merck & Co Inc's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
Merck & Co Inc's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
MRK Solvency Score
Solvency Due Diligence
Merck & Co Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Merck & Co Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MRK Price Targets Summary
Merck & Co Inc
According to Wall Street analysts, the average 1-year price target for MRK is 139.76 USD with a low forecast of 119.18 USD and a high forecast of 155.4 USD.
Ownership
MRK Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
MRK Price
Merck & Co Inc
Average Annual Return | 17.74% |
Standard Deviation of Annual Returns | 26.05% |
Max Drawdown | -27% |
Market Capitalization | 318.4B USD |
Shares Outstanding | 2 533 029 888 |
Percentage of Shares Shorted | 0.77% |
MRK News
Last Important Events
Merck & Co Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Merck & Co Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Kenilworth, New Jersey and currently employs 68,000 full-time employees. The firm offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The company operates through two segments: Pharmaceutical and Animal Health. The firm's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The firm sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species.
Contact
IPO
Employees
Officers
The intrinsic value of one MRK stock under the Base Case scenario is 135.96 USD.
Compared to the current market price of 125.78 USD, Merck & Co Inc is Undervalued by 7%.